Skip to content
DraconiticResearch
Search Sources API
190,839 studies31 sourcesUpdated 8 min ago
Peer-reviewedCC BYFrontiers in endocrinology

Commentary: Selpercatinib versus multi-kinase inhibitors for advanced medullary thyroid cancer: a network meta-analysis of RET-targeted therapies.

  • Arnau Domenech1
  • Martí Hopmans1
  • Erin Barker2
  • Joe W E Moss2
  • Montserrat Carrasco1
  1. 1Esteve Pharmaceuticals S.A., Barcelona, Spain.
  2. 2York Health Economics Consortium, University of York, York, United Kingdom.
Read full textPDFDOICite

Related

  1. Commentary: Hemophagocytic lymphohistiocytosis induced by immune checkpoint inhibitors: observations and proposed clinical management
    Gauthier Coussement, Maxime Ilzkovitz, Loïc Baudelet +2
    Frontiers in ImmunologyPeer-reviewedCC BY 4.0Full textImmunologyGeneral medicineCrossrefDOAJ
  2. Advanced Therapies for the Management of Immune Checkpoint Inhibitor-Induced Colitis
    Cosimo Simone Matichecchia, Fabrizio Fanizzi, Alessandra Zilli +7
    CancersPeer-reviewedCC BYFull textOncologyEurope PMC
  3. Integrating overall survival and health-related quality of life to prioritize first-line systemic therapies for unresectable advanced gastric cancer: a network meta-analysis
    Ji Wu, Zhigang Zheng, Xiping Shen +2
    Frontiers in oncologyPeer-reviewedCC BYFull textOncologyEurope PMC
  4. Impact of Smoking on the Effectiveness of Advanced Therapies in Inflammatory Bowel Disease: Active Smoking Is Associated with Reduced Effectiveness of Anti-TNF Treatment
    Sofia Cinque, Maria Laura Annunziata, Antonella Bianchi +7
    Medicina (Kaunas, Lithuania)Peer-reviewedCC BYFull textGeneral medicineEurope PMC
  5. Oral Targeted Therapies and Clinician Comanagement Among Men With Advanced Prostate Cancer
    Arnav Srivastava, Anqi Sun, Megan E. V. Caram +2
    JAMA Network OpenPeer-reviewedCC BY 4.0General medicineCrossref

Cite

BibTeXRIS
BibTeX
@article{domenech2026commentary,
  title = {{Commentary: Selpercatinib versus multi-kinase inhibitors for advanced medullary thyroid cancer: a network meta-analysis of RET-targeted therapies.}},
  author = {Arnau Domenech and Martí Hopmans and Erin Barker and Joe W E Moss and Montserrat Carrasco},
  journal = {Frontiers in endocrinology},
  year = {2026},
  month = oct,
  doi = {10.3389/fendo.2026.1979615},
  url = {https://europepmc.org/article/MED/42898225},
  note = {CC BY},
}
RIS
TY  - JOUR
TI  - Commentary: Selpercatinib versus multi-kinase inhibitors for advanced medullary thyroid cancer: a network meta-analysis of RET-targeted therapies.
AU  - Arnau Domenech
AU  - Martí Hopmans
AU  - Erin Barker
AU  - Joe W E Moss
AU  - Montserrat Carrasco
PY  - 2026
DA  - 2026/10/05
JO  - Frontiers in endocrinology
DO  - 10.3389/fendo.2026.1979615
UR  - https://europepmc.org/article/MED/42898225
SN  - 1664-2392
ER  -